New algorithm aims to personalize stroke rehab and speed recovery

NCT ID NCT04637984

Completed Knowledge-focused Sponsor: University Hospital of Ferrara Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a tool called PREP2 can help doctors better predict how well stroke patients will recover arm and leg function. The tool combines simple strength tests and brain measurements in the first days after a stroke. Researchers hope that using these predictions will allow therapists to tailor rehabilitation, making it more efficient and improving outcomes for the 200 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PREP2 algorithm (a combination of clinical assessments and brain measurements to predict recovery)
What this could lead to: If successful, this approach could help doctors and therapists create more personalized rehabilitation plans, potentially speeding up recovery and improving independence after stroke.
What could go wrong: This is a single-site trial with 200 participants, so results may not apply to all stroke patients. The algorithm is a prediction tool, not a treatment, so its impact on actual recovery is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REHABILITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REHABILITATION STROKE

Contacts and locations

Locations

Department of Neuroscience and Rehabilitation, University Hospital of Ferrara

Ferrara, Emilia-Romagna, 44124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.